Piotr Kozlowski1, Ran Meng2, Burkhard Meadler3, Silvia D. Chang4, Edward C. Jones5, S Larry Goldenberg6
1The Prostate Centre at VGH, Vancouver, BC, Canada; 2UBC MRI Research Centre, Vancouver, BC, Canada; 3Philips Healthcare, Vancouver, BC, Canada; 4Radiology, University of British Columbia, Vancouver, BC, Canada; 5Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; 6Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
DTI and DCE MRI were carried out in 18 prostate cancer patients. Mean diffusivity, fractional anisotropy and pharmacokinetic modeling parameters calculated from MRI data were correlated with biopsy. All MRI parameters, with the exception of extra-cellular extra-vascular space, showed significant differences between cancer and benign prostate. Sensitivity and specificity of the DTI data were 86% and 89% respectively, and 66% and 94% for the DCE data. When both ADC and DCE results were combined the sensitivity increased to 91% while specificity lowered to 85%. Combined DTI and DCE MRI provide better prostate cancer diagnosis than each technique alone.